Yes, as I note in the article.

The best-fit hypothesis is that there is no way to control manufacturing at-scale when the product causes the body to produce a pathogenic thing via a biological process.

All drugs have a toxic dose. You can control direct introduction of a drug sufficiently to prevent toxicity on a random lot-based basis. What you can't do, on the evidence, is sufficiently control that process when the body itself is doing the manufacturing.

If the thing manufactured is benign this might not matter but in the case of a coronavirus it matters greatly since the spike is pathogenic even without the rest of the virus.

----------